LONDON, 7 September 2017:

Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), an Arix Bioscience Group Business, of positive top-line results from its Phase 2a clinical trial for RPL554 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

The data from this Phase 2a trial demonstrated statistically significant and clinically meaningful improvement in peak lung function and a faster onset of action when Verona Pharma’s RPL554 was added to tiotropium (Spiriva®), one of the most commonly used drugs to treat COPD, versus tiotropium alone.

The double-blind, placebo-controlled, three way cross-over trial in 30 subjects with moderate-to-severe COPD demonstrated statistical significance across all primary and secondary efficacy outcome measures at the 6mg dose, a clear dose response compared to the 1.5mg dose, and both doses of RPL554 were well tolerated.

RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the maintenance treatment of COPD patients and for the treatment of patients with cystic fibrosis.

Verona Pharma continues to enroll patients in its Phase 2b study to assess nebulised RPL554 for the maintenance treatment of COPD.

“We are very pleased to note Verona Pharma’s positive trial data, which clearly demonstrates the clinical benefit of its product as an add-on treatment to one of the most widely prescribed drugs for COPD. Verona Pharma is a dynamic company with an important drug asset, and today’s data further reinforces our belief in its potential to address significant unmet needs in respiratory medicine.”

Joe Anderson, Chief Executive Officer of Arix Bioscience